FLR
70
-5
TMO
40
-2
KSS
20
-3
AAPL
42
-3
RHI
40
-3
AXP
49
-3
SHW
36
-12
AME
56
-4
EA
25
-3
NUE
31
-6
DO
48
-2
CCI
10
-2
FSLR
41
-2
ROST
47
-3
MAS
34
-2
AA
31
4
CME
42
-3
INTC
45
-7
APH
36
-3
FTI
84
-2
FLR
70
-5
TMO
40
-2
KSS
20
-3
AAPL
42
-3
RHI
40
-3
AXP
49
-3
SHW
36
-12
AME
56
-4
EA
25
-3
NUE
31
-6
DO
48
-2
CCI
10
-2
FSLR
41
-2
ROST
47
-3
MAS
34
-2
AA
31
4
CME
42
-3
INTC
45
-7
APH
36
-3
FTI
84
-2
Financhill
Back

Akero Therapeutics Quote, Financials, Valuation and Earnings

First Disruption to Smartphones in 15 Years

Disclosure: Please read the offering circular at invest.modemobile.com. This is a paid advertisement for Mode Mobile's Regulation CF Offering.
Buy
53

AKRO
Akero Therapeutics

Last Price:
48.58
Seasonality Move:
9.48%

7 Day Trial

ALL ACCESS PASS

$ 7

[Free Copy] Hedge Fund Black Book

Send Me My Free Copy!

Akero Therapeutics Price Quote

$48.58
-0.02 (-5.38%)
(Updated: September 21, 2023 at 5:09 AM ET)

Akero Therapeutics Key Stats

Buy
53
Akero Therapeutics (AKRO) is a Buy
Day range:
$48.52 - $51.81
52-week range:
$25.21 - $58.38
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
4.38%
Volume:
1.2M
Avg. volume:
857.8K
1-year change:
85%
Market cap:
$2.7B
Revenue:
$0
EPS:
$-2.56

How Much Does Akero Therapeutics Make?

Data Unavailable

Is Akero Therapeutics Growing As A Company?

Data Unavailable

Akero Therapeutics Stock Price Performance

What Is Akero Therapeutics 52-Week High & Low?

Akero Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akero Therapeutics?

Is Akero Therapeutics Cash Flow Positive?

  • What Is AKRO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$97.2M
  • What Is Akero Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $572.6M
  • What Is Akero Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$209.2M

Akero Therapeutics Return On Invested Capital

Data Unavailable

Akero Therapeutics Earnings Date & Stock Price

Akero Therapeutics Competitors

  • Who Are Akero Therapeutics's Competitors?
    Below is a list of companies who compete with Akero Therapeutics or are related in some way:
    • ADMA Biologics Inc (ADMA)
    • Eli Lilly and Co (LLY)
    • Madrigal Pharmaceuticals Inc (MDGL)
    • Reata Pharmaceuticals Inc (RETA)
    • Viking Therapeutics Inc (VKTX)

Akero Therapeutics Dividend Yield

Data Unavailable

Akero Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 11.77%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 6
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 67.89
Upside from Last Price: 39.69%

Major Shareholders

  • How many AKRO shares are owned by institutional investors?
    80.9M AKRO shares are owned by institutional investors
  • How many AKRO shares are owned by insiders?
    1M AKRO shares are owned by insiders